Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT: NCT02928497 · COMPLETED

NCT IDNCT02928497
StatusCOMPLETED
Start Date2017-02-06
Completion2025-09-23

Brief Summary

The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

Frequently Asked Questions

What is Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation?

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation is a clinical trial registered under NCT02928497. Current status: COMPLETED.

What is the status of NCT02928497?

The current status of NCT02928497 (Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation) is: COMPLETED.

When did Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation start?

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation started on 2017-02-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑